We checked that AS602868 effectively targeted canonical NF-kB pathway in breast cancer cells by evaluating its capacity to counteract TNFα-induced activation of NF-kB transcription using a NF-kB gene reporter assay and to potentiate TNFα-induced cell death. The gene discussed is NFKB1; the disease is breast cancer.